Fulcrum Therapeutics exchanges 9.35M shares for pre-funded warrants with RA Capital and another stockholder

Fulcrum Therapeutics, Inc.

RA Capital exchanged 8,500,000 shares for a pre-funded warrant for 8,500,000 shares at $0.001 exercise price, no expiration.
Another institutional stockholder exchanged 850,000 shares for pre-funded warrants for 850,000 shares on same terms.
Beneficial ownership blocker set at 9.99%; RA Capital can increase to 19.99% with 61 days' notice.
No cash proceeds to Fulcrum; exchange exempt from registration under Section 3(a)(9) of the Securities Act.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.